BLOG

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

In Step 1 of the Phase III Atalante 1 trial, OSE Immunotherapeutics’ investigational agent Tedopi improved the 12-month survival rate over chemotherapy in patients with HLA-A2 positive non-small cell lung cancer who faile